



IBA Signs Contract with Tata Memorial Centre to Install Proton Therapy Center in India

Contract worth approximately EUR 60 million to IBA including a long-term operation and maintenance contract

Louvain-la-Neuve, Belgium, March 10, 2016 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that, following a global public tender, it has signed a contract with Tata Memorial Centre, to install a proton therapy center in Mumbai, India.

IBA will equip the new center with its Proteus®PLUS multi-room configuration including three treatment rooms with Pencil Beam Scanning capability. The equipment and services supplied by IBA will be worth approximately EUR 60 million to IBA. The project is fully financed and includes a long-term operation and maintenance contract. The center will treat its first patient in 2019.

Olivier Legrain, Chief Executive Officer of IBA, commented: *“Following a rigorous public tender process, we are delighted that IBA has been selected by Tata Memorial Centre to deliver a new Proton Therapy system in Mumbai, India. The Indian healthcare market is growing rapidly and there is a significant need for innovative approaches to cancer therapies that are made available to a wider patient pool. Tata Memorial Centre is a leading hospital in India with a strong oncology practice, and, through this collaboration, IBA further strengthens its leading position in proton therapy in the region.”*

Dr Rajendra Badwe, Director of Tata Memorial Centre, commented: *“Tata Memorial Centre is pleased to be working with IBA to install the first publicly funded proton therapy center in India. IBA is the market leader in the provision of proton therapy and their experience and technological leadership, including the ability to offer Pencil Beam Scanning Technology, made them our partner of choice. We look forward to offering proton therapy, a revolutionary treatment for many cancer indications, to patients in India & the region, whilst also conducting research focused at evaluating the role of proton therapy for these indications.”*

With approximately three million people suffering from cancer in India and one million new cases detected every year, there is a need for specialty cancer care centers. Establishment of the Tata Memorial Centre, Proton Therapy facility would make another state of the art treatment available to many who could benefit from this advanced technology.

end



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1200 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About Tata Memorial Center

The Tata Memorial Centre (TMC) is a comprehensive cancer care center, located in Mumbai and is under the administrative control of the Department of Atomic Energy, Government of India. It is internationally recognized as a leader in health care, with a reputation for excellence in patient care, research, and medical education. TMC is ranked amongst the top cancer care centers globally catering to 55-60 thousand new cancer patients every year. TMC not only caters to patients from within the country but also from the neighboring countries.

Apart from Service, TMC is also involved in Research and Training of personnel in various aspects of cancer care. Clinical trials conducted at TMC are reviewed by the Institutional Ethics Committee (IEC) that is recognized & accredited by national regulatory bodies & international organisations like Association for Accreditation of Human Research Protection Programs (AAHRPP) and Forum for Ethical Review Committees in Asia & Pacific (FERCAP).

For further information please contact:

IBA

Jean-Marc Bothy
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
Communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com

Rx Communications Group (US)

Melody Carey
+ 1 917 322 2571
mcarey@RxIR.com